San Antonio Breast Cancer Symposium.
Fricker
Janet
J
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001943:Breast Neoplasms / Q000188:drug therapy*; D004164:Diphosphonates / Q000627:therapeutic use*; D000068338:Everolimus; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D000077341:Lapatinib; D000077289:Letrozole; D009570:Nitriles / Q000008:administration & dosage*; D011799:Quinazolines / Q000008:administration & dosage*; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013629:Tamoxifen / Q000627:therapeutic use*; D000068878:Trastuzumab; D014230:Triazoles / Q000008:administration & dosage*; D000077211:Zoledronic Acid
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004164:Diphosphonates; D007093:Imidazoles; D009570:Nitriles; D011799:Quinazolines; D014230:Triazoles; D013629:Tamoxifen; D000077341:Lapatinib; D000077211:Zoledronic Acid; D000077289:Letrozole; D000068338:Everolimus; D000068878:Trastuzumab; D020123:Sirolimus